Trials / Completed
CompletedNCT01546532
Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Renal Hemodynamic Effects of RLX030 and Placebo Infused for 24 Hours in Subjects With Chronic Heart Failure (CHF)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the renal hemodynamic effect of RLX030 infusion in subjects with chronic heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RLX030 | RLX030 as intravenous infusion for 24 hours. |
| DRUG | Placebo | Intravenous infusion of Placebo over 24 hours |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2012-03-07
- Last updated
- 2020-12-19
Locations
15 sites across 4 countries: United States, Germany, Netherlands, Poland
Source: ClinicalTrials.gov record NCT01546532. Inclusion in this directory is not an endorsement.